Abstract
Chemotherapy-induced thrombotic microangiopathy is a severe illness that has occurred in a small number of patients treated with carboplatin and combination of docetaxel and trastuzumab chemotherapy. We describe herein the case of a patient with stage IIB breast cancer who developed thrombotic microangiopathy after five cycles of carboplatin, docetaxel, and trastuzumab.
MeSH terms
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / blood*
-
Breast Neoplasms / drug therapy*
-
Carboplatin / administration & dosage
-
Carboplatin / adverse effects
-
Chemotherapy, Adjuvant
-
Docetaxel
-
Female
-
Humans
-
Middle Aged
-
Receptor, ErbB-2 / biosynthesis
-
Taxoids / administration & dosage
-
Taxoids / adverse effects
-
Thrombotic Microangiopathies / chemically induced*
-
Trastuzumab
Substances
-
Antibodies, Monoclonal, Humanized
-
Taxoids
-
Docetaxel
-
Carboplatin
-
Receptor, ErbB-2
-
Trastuzumab